Wednesday, April 20, 2016

BRIEF-Mitsubishi Tanabe Pharma's ALS study meets primary efficacy endpoint

* Mitsubishi Tanabe Pharma Corporation presents Edaravone

clinical trial data in ALS at 2016 American Academy of Neurology

annual meeting

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)